A SBIR Phase I contract was awarded to Embody, Inc. in October, 2021 for $49,768.0 USD from the U.S. Department of Defense and United States Air Force.
Embody, Inc. has pioneered a breakthrough, scalable, and robust biomanufacturing approach producing musculoskeletal tissue-like constructs to improve the treatment, recovery rate, and regeneration of commonly injured muscles, ligaments, and tendons among